Novartis AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novartis with three other
pharmaceutical manufacturers in Europe:
sales of 41.40 billion Euros [US$49.58 billion]
of which 46%
(37.37 billion Euros [US$44.75 billion]
of which 69%
was Pharmaceuticals), and
based in UNITED KINGDOM
(£34.10 billion [US$46.97 billion]
of which 50%
Novartis reported sales of 46.58 billion Swiss Francs (US$50.46 billion)
December of 2020.
decrease of 3.6%
versus 2019, when the company's sales were 48.29 billion Swiss Francs.
The sales level in 2020 was fairly close to the level five years ago: in 2015, Novartis had sales
of 48.55 billion Swiss Francs.
Contributing to the drop in overall sales was the 6.8% decline
in Sandoz, from 9.66 billion Swiss Francs to 9.00 billion Swiss Francs.
There were also decreases in sales in
Innovative Medicines (down 2.8% to 36.42 billion Swiss Francs)